A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Hinge Health, Inc. HNGE
Promising (early) broader-coverage candidate · Established in 2012 and headquartered in San Francisco, California, Hinge Health, Inc.
On FrontierLab's discovery record since 2026-06-23 (8 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-08-01), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 49.8% |
|---|---|
| Gross margin | 80.8% |
| Gross profits / assets | 0.72 |
| Rule of 40 | -31.8 |
| Net margin | -81.6% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 8.9 |
Quality checklist
- ✓ Revenue growth — 49.8% (pass ≥ 20%)
- ✓ Capital efficiency
- ✓ Gross margin — 80.8% (pass ≥ 60%)
- ~ Gross-margin trend — 1.5 (pass ≥ 2)
- ✓ Share dilution — 5.6%
Fundamentals — snapshot as of 2026-08-01
| Stage | Early |
|---|---|
| Share issuance (YoY) | 5.6% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-6.62 |
| Burn multiple | — |
| Gross-margin trend (pts) | 1.5 |
| Cash / assets | 0.44 |
| Net debt / EBITDA | — |
| Statements as of | Q1 FY2026 · filed 2026-05-07 |
Momentum context — a snapshot from 2026-08-01, not current
| Price at surface | $74.71 (as of 2026-08-01) |
|---|---|
| 52-week range | $30.08 – $91.5 |
| % off 52-wk high | -18.3% |
| RSI (14) | 42 |
| Relative volume | 0.5× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-08-01 (end-of-day). How grades are computed →